Enoxaparin experience in percutaneous coronary intervention.
To investigate the efficacy and safety of enoxaparin in 135 consecutive patients who were undergoing emergency/non-emergency percutaneous coronary intervention (PCI), a prospective, observational study of procedural anticoagulation was carried out with enoxaparin in elective, primary PCI. Documentation of the in-hospital clinical and angiographic outcomes was performed in eligible patients undergoing elective or primary PCI. This data helped to capture how patients while on anticoagulation with enoxaparin were being managed. As this was a prospective observational registry and not a randomised controlled trial, there was no single hypothesis from which to calculate the minimum sample size required. We recorded outcomes with 135 consecutive patients undergoing PCI who were enrolled in the study. While analysing the results the points taken into consideration were: Patient demography, PCI, methods of haemostasis and timing of sheath removal, dose and timing of enoxaparin and clinical and angiographic outcome. Statistical analysis was performed using statistical analysis system (SAS) software. Enoxaparin when used in PCI, can be a safe alternative to unfractionated heparin (UFH).
Somani
V
V
CHL-Apollo Hospital, Indore.
Trivedi
S
S
D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000628:therapy*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D017984:Enoxaparin; D005343:Fibrinolytic Agents